Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David A. Reardon, Lakshmi Nayak, Katherine B. Peters, Jennifer Leigh Clarke, Justin T Jordan, John Frederick De Groot, Phioanh Leia Nghiemphu, Thomas Joseph Kaley, Howard Colman, Sarah C. Gaffey, Victoria Caruso, Myriam Bednarek Debruyne, Chinmay Bhavsar, Annette M Molinaro, Timothy Smith, Mariano Severgnini, Patrick Y. Wen
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Duke Medical Center, University of California, San Francisco, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Memorial Sloan Kettering Cancer Center, Huntsman Cancer Institute, Dana-Farber Brigham Cancer Center, Brigham and Women's Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891790331